Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results Fourth quarter revenue growth of 19% to $29.5 million2025 revenue growth of 20% to $107.9 millionConference call with Q&A today ...
Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug ...
Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results